Bluefish Pharmaceuticals
Jaya Ramakrishnan has extensive experience in regulatory affairs, currently serving as General Manager- Regulatory Affairs and Director at Bluefish Pharmaceuticals since March 2017, focusing on the development and implementation of regulatory strategies for product approvals. Previously, Jaya held the position of Head of Regulatory - Critical Regulatory Affairs Solutions at Concordia International Corp, overseeing strategic regulatory inputs and due diligence for acquisitions from November 2003 to February 2017. Jaya also led regulatory efforts at AMCo and Goldshield Pharmaceuticals Limited, managing large teams and directing crucial corporate projects. An earlier role as Executive Regulatory Affairs at CIPLA Ltd. involved educating and assisting manufacturing units with registration requirements. Jaya's career began as a trainee analyst at GEO-CHEM LABS. Jaya holds a Bachelor of Pharmacy from Bombay College of Pharmacy and is a Certified Internal Quality Auditor.
This person is not in the org chart
This person is not in any offices
Bluefish Pharmaceuticals
Founded in Sweden, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive generics pharmaceuticals companies. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. Bluefish currently conducts operations in 19 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. Our corporate culture and close collaboration with development and manufacturing partners are integral parts of our effort to deliver quality products at affordable prices. We offer a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.